Literature DB >> 15862412

Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart.

Richard D Patten1, David Denofrio, Mohamad El-Zaru, Rahul Kakkar, Jessica Saunders, Flore Celestin, Kenneth Warner, Hassan Rastegar, Kamal R Khabbaz, James E Udelson, Marvin A Konstam, Richard H Karas.   

Abstract

OBJECTIVES: We examined the effect of mechanical unloading with ventricular assist device (VAD) therapy on myocardial inducible nitric oxide synthase (iNOS) expression and cardiomyocyte apoptosis in patients with end-stage heart failure (HF).
BACKGROUND: Despite advances in medical therapy, HF continues to be a progressive and ultimately fatal disorder. High levels of iNOS expression are present in the myocardium of failing hearts, suggesting a potential role for iNOS in HF progression.
METHODS: Inducible NOS protein expression was analyzed by Western blotting and cardiomyocyte apoptosis by terminal deoxynucleotidyltransferase dUTP nick end-labeling (TUNEL) in myocardial samples from failing hearts. Included in these analyses were tissues from 9 patients at the time of transplantation (HF-transplant group), 10 patients at the time of VAD insertion (pre-VAD group), and 11 patients undergoing transplant after VAD support (post-VAD group). Seven control samples were obtained at autopsy.
RESULTS: Low or undetectable levels of iNOS were present in controls (0.005 +/- 0.002). The HF-transplant and pre-VAD myocardial specimens exhibited a marked increase in iNOS expression (1.48 +/- 0.34 and 1.29 +/- 0.26, respectively; p < 0.01 for both vs. controls). The increase in iNOS expression was reversed in the post-VAD group (0.36 +/- 0.16; p < 0.01 vs. HF-transplant and pre-VAD groups). The rate of TUNEL-positive cardiomyocytes was high in the pre-VAD group and significantly lower in the post-VAD group (0.64 +/- 0.15% in pre-VAD group and 0.16 +/- 0.07% in post-VAD group; p < 0.01). The iNOS levels correlated significantly with cardiomyocyte apoptosis (r = 0.66, p < 0.01).
CONCLUSIONS: Therapy with VAD normalizes iNOS expression in association with diminished cardiomyocyte apoptosis in the failing heart. Further work is required to define whether a causal relationship exists between iNOS and cardiomyocyte apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15862412     DOI: 10.1016/j.jacc.2004.05.090

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

1.  Helix-loop-helix protein p8, a transcriptional regulator required for cardiomyocyte hypertrophy and cardiac fibroblast matrix metalloprotease induction.

Authors:  Sandro Goruppi; Richard D Patten; Thomas Force; John M Kyriakis
Journal:  Mol Cell Biol       Date:  2006-11-20       Impact factor: 4.272

Review 2.  Building a bridge to recovery: the pathophysiology of LVAD-induced reverse modeling in heart failure.

Authors:  Shigeru Miyagawa; Koichi Toda; Teruya Nakamura; Yasushi Yoshikawa; Satsuki Fukushima; Shunsuke Saito; Daisuke Yoshioka; Tetsuya Saito; Yoshiki Sawa
Journal:  Surg Today       Date:  2015-04-04       Impact factor: 2.549

Review 3.  Vagus nerve stimulation in experimental heart failure.

Authors:  Hani N Sabbah; Itamar Ilsar; Asaph Zaretsky; Sharad Rastogi; Mengjun Wang; Ramesh C Gupta
Journal:  Heart Fail Rev       Date:  2011-03       Impact factor: 4.214

4.  Dynamic patterns of ventricular remodeling and apoptosis in hearts unloaded by heterotopic transplantation.

Authors:  Henriette Brinks; Marie-Noelle Giraud; Adrian Segiser; Celine Ferrié; Sarah Longnus; Nina D Ullrich; Walter J Koch; Patrick Most; Thierry P Carrel; Hendrik T Tevaearai
Journal:  J Heart Lung Transplant       Date:  2013-10-04       Impact factor: 10.247

5.  Overexpression myocardial inducible nitric oxide synthase exacerbates cardiac dysfunction and beta-adrenergic desensitization in experimental hypothyroidism.

Authors:  Qun Shao; Heng-Jie Cheng; Michael F Callahan; Dalane W Kitzman; Wei-Min Li; Che Ping Cheng
Journal:  Int J Cardiol       Date:  2015-11-06       Impact factor: 4.164

Review 6.  Baroreflex activation for the treatment of heart failure.

Authors:  Hani N Sabbah
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

7.  Hypertension in African Americans with heart failure: progression from hypertrophy to dilatation; perhaps not.

Authors:  Pallavi Solanki; Ramzan M Zakir; Rajiv J Patel; Sri-Ram Pentakota; James Maher; Christine Gerula; Muhamed Saric; Edo Kaluski; Marc Klapholz
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-11-20

8.  Modulation of stretch-induced myocyte remodeling and gene expression by nitric oxide: a novel role for lipoma preferred partner in myofibrillogenesis.

Authors:  Charlotte L Hooper; Anju Paudyal; Philip R Dash; Samuel Y Boateng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-03-15       Impact factor: 4.733

Review 9.  Intervention for apoptosis in cardiomyopathy.

Authors:  Hiroyuki Yaoita; Yukio Maruyama
Journal:  Heart Fail Rev       Date:  2008-06       Impact factor: 4.214

10.  Ablation of iNOS delays cardiac contractile dysfunction in chronic hypertension.

Authors:  Fernando A L Dias; Dalia Urboniene; Milana A Yuzhakova; Brandon J Biesiadecki; James R Pena; Paul H Goldspink; David L Geenen; Beata M Wolska
Journal:  Front Biosci (Elite Ed)       Date:  2010-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.